Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
about
Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specificAnthracycline- and trastuzumab-induced cardiotoxicity: a retrospective studyIntersection of cardiology and oncology clinical practices.Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.Chemotherapy-induced cardiomyopathy in breast cancer patients.Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryEradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fearsShifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study.Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors.Gemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicity.Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation, and ApoptosisHistamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model.Periodically Pulsed Immunotherapy in a Mathematical Model of Tumor, CD4+ T Cells, and Antitumor Cytokine Interactions.Men With a Terminal Illness Relax Their Criteria for Facial Attractiveness.Subcutaneous Ehrlich Ascites Carcinoma mice model for studying cancer-induced cardiomyopathy.Bevacizumab: A Rare Cause of Nonischemic Cardiomyopathy
P2860
Q27301261-F5E55E9A-6B2F-42E3-B83A-65A301FE7C19Q30276527-49AFA44F-5FA1-47D6-AF2E-CA9B9B791136Q30428702-1F9724C3-E734-4E25-B1B7-30BB1B7F2813Q33162850-DAFCC63A-EF8A-4CA1-A30A-C47833011A7CQ33653485-D9DF0CB4-6E33-4CD2-AA06-0AFAC2BA16ACQ34621237-0FDBAA0E-C61A-49A5-A9A8-984917EA748BQ35039202-0F1B3635-9ECD-47F6-8416-9CCB09CADB87Q35109273-8B5FF5D9-AA5F-44E8-B73C-2AE17BDF1DBDQ35588736-9C6CA220-6140-46E7-A71C-78C7087D4FDAQ35774310-CEDA0A8D-198C-46B3-B1CF-10D57C2CDE3AQ35880045-AB64C190-8B86-4E91-AC97-7C9A1F842248Q37378179-B33244E3-B1F2-4C57-8CAB-505F6843BEE0Q39010412-AA5DD421-A884-4032-81E4-CA4024BE4990Q41846538-877CCD7D-7F40-4FEB-AE4A-6BFDEA06C21CQ42542336-E3D3884A-1F34-4463-B7EF-C2938CE37BF2Q46309853-BBE81673-9695-4EED-8167-C7CF876352B5Q47099396-0CE0BD69-3293-428B-AC62-A9B5057ADFD2Q47101092-1D191C70-90AA-4DDD-8495-AA94E45DD7F3Q55002400-67795573-A946-48C4-A6C3-6008546410C3Q58700422-1108BB69-5FCB-4F0F-86AC-BFF0832BE09B
P2860
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
@ast
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
@en
type
label
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
@ast
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
@en
prefLabel
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
@ast
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
@en
P2860
P1476
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management
@en
P2093
Douraid K Shakir
Kakil I Rasul
P2860
P356
10.4021/JOCMR2009.02.1225
P577
2009-03-24T00:00:00Z